Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC

Launched by TURKU UNIVERSITY HOSPITAL · Apr 12, 2021

Keywords

ClinConnect Summary

This clinical trial, called the DECIDER project, is studying how to better diagnose and treat high-grade serous ovarian cancer (HGSOC), a type of cancer that often spreads quickly and becomes resistant to chemotherapy. The goal is to understand why some patients do not respond well to treatment and to develop personalized therapies that can help them. Researchers are looking for women aged 18 and older who have been diagnosed with advanced-stage HGSOC and are being treated at Turku University Hospital. Participants will undergo regular monitoring throughout their treatment, with samples collected from tumors and blood to analyze how the cancer behaves and how it responds to different therapies.

If you join the trial, you can expect to have your health closely tracked, with various tests and samples taken to gather important information about your cancer. This research aims to create new tools and methods to help doctors make better treatment decisions for patients with HGSOC. It's important to know that not everyone with ovarian cancer will be eligible for this study, especially those with certain health conditions or age limits. Your participation could contribute to significant advancements in understanding and treating this challenging disease.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients with a suspected ovarian cancer diagnosis treated at the Turku University Hospital
• • Ability to understand and the willingness to sign a written informed consent document
• Exclusion Criteria:
• • Age \<18 years, too poor condition for active treatment (surgery, chemotherapy)
• • FDG PET/CT scan is not performed for patients with diabetes mellitus and poor glucose balance.